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Abstract
Background—Low human papillomavirus (HPV) vaccination coverage stands in stark contrast 
to our success in delivering other adolescent vaccines. To identify opportunities for improving 
physicians’ recommendations for HPV vaccination, we sought to understand how the 
communication context surrounding adolescent vaccination varies by vaccine type.
Methods—A national sample of 776 U.S. physicians (53% pediatricians, 47% family medicine 
physicians) completed our online survey in 2014. We assessed physicians’ perceptions and 
communication practices related to recommending adolescent vaccines for 11- and 12-year-old 
patients.
Results—About three-quarters of physicians (73%) reported recommending HPV vaccine as 
highly important for patients, ages 11–12. More physicians strongly recommended tetanus, 
diphtheria, and acellular pertussis (Tdap) (95%) and meningococcal vaccines (87%, both p<0.001) 
for this age group. Only 13% of physicians perceived HPV vaccine as being highly important to 
parents, which was far fewer than perceived parental support for Tdap (74%) and meningococcal 
vaccines (62%, both p<0.001). Physicians reported that discussing HPV vaccine took almost twice 
as long as discussing Tdap. Among physicians with a preferred order for discussing adolescent 
vaccines, most (70%) discussed HPV vaccine last.
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Conclusions—Our findings suggest that primary care physicians perceived HPV vaccine 
discussions to be burdensome, requiring more time and engendering less parental support than 
other adolescent vaccines. Perhaps for this reason, physicians in our national study recommended 
HPV vaccine less strongly than other adolescent vaccines, and often chose to discuss it last. 
Communication strategies are needed to support physicians in recommending HPV vaccine with 
greater confidence and efficiency.
Keywords
adolescent health; human papillomavirus infections/prevention & control; health communication; 
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INTRODUCTION
Human papillomavirus (HPV) vaccination rates among U.S. adolescents are not on track to 
meet the Healthy People 2020 goal of 80% coverage.1 By 2013, only 35% of adolescent 
girls and 14% of adolescent boys completed the three-dose HPV vaccine series.2 For girls, 
this level of coverage represents an increase of just three percentage points since 2010.2,3 By 
contrast, coverage levels for two other adolescent vaccines, tetanus, diphtheria, and acellular 
pertussis (Tdap) and meningococcal vaccines, have risen dramatically over the same time 
period, reaching 86% and 78%, respectively.2 This success demonstrates that delivering 
vaccines to adolescents is possible and raises questions about why HPV vaccination 
coverage remains so low.2
Research suggests that improving healthcare providers’ communication is among the most 
important strategies for increasing HPV vaccine uptake in the U.S., where the vast majority 
of HPV vaccine doses are delivered in the context of primary care.4,5 Although a provider’s 
recommendation is a strong and consistent predictor of HPV vaccination,6–10 many parents 
of age-eligible adolescents do not receive recommendations.4 Furthermore, the available 
evidence suggests that providers often give weak HPV vaccine recommendations.11–14 For 
example, in a survey we conducted with primary care providers, one-quarter reported that 
they do not recommend HPV vaccine as strongly as other adolescent vaccines for 11- and 
12-year-old girls, and over half indicated that they prefer to offer HPV vaccine as an 
“optional” vaccine for this age group.13 Weak recommendations for HPV vaccine are 
problematic because they likely convey ambivalence to adolescents and their parents, 
particularly when juxtaposed against stronger recommendations for other adolescent 
vaccines.11–14
To better understand HPV vaccination in relation to other adolescent vaccines, we surveyed 
a national sample of primary care physicians to assess perceptions and communication 
practices related to recommending HPV, Tdap, and meningococcal vaccines. As one of the 
first studies to locate HPV vaccination within the broader context of adolescent 
immunization, our research aims to identify opportunities for better aligning communication 
about HPV vaccination with the successful strategies providers already employ to support 
Tdap and meningococcal vaccination.
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We conducted a national, online survey of pediatricians and family physicians in April to 
June 2014. Physicians were members of a standing panel maintained by a survey research 
company.15 Identified through American Medical Association lists, panel members included 
similar numbers of family physicians (51%) and pediatricians (49%) who were located in all 
regions of the U.S. (22% Northeast; 23% Midwest; 37% South; 18% West). For this study, 
panel members were eligible to participate if they provided preventive care, including 
vaccinations, to 11- and 12-year-old patients. Our survey focused on patients in this age 
range because national guidelines recommend ages 11 and 12 for the routine administration 
of adolescent vaccines.
The survey company emailed invitations to all 2,368 panel members with pediatric or family 
medicine specialties, and 1,022 physicians (43%) responded by visiting the survey website. 
Of these, 776 (76%) met eligibility criteria, provided informed consent via the website, and 
completed the online survey. Physicians received incentives of $25 to $45 for completing 
our survey, with higher incentives used to maximize participation later in the fielding 
process. The University of North Carolina Institutional Review Board approved the study 
protocol.
Measures
Our survey assessed physicians’ perceptions and communication practices with regard to 
adolescent vaccines. Separately for HPV, Tdap, and meningococcal vaccines, physicians 
indicated how important they say each vaccine is when recommending it for patients, ages 
11–12. Physicians also indicated how important they believe parents feel each vaccine is for 
their 11- and 12-year-old children. We categorized responses of “extremely” or “very” 
important as indicating high vaccine endorsement, while responses of “moderately,” 
“slightly,” or “not” important indicated low vaccine endorsement.
Physicians indicated which of the three adolescent vaccines they usually discuss first and 
last. They estimated, in minutes and seconds, how long it usually takes to talk about each 
vaccine. One item assessed which of the three vaccines, if any, physicians discuss during 
sick visits for patients with mild complaints. For physicians who did not indicate all three 
vaccines, a follow-up item assessed their reason(s) for not discussing adolescent vaccines 
during sick visits. As in the case of vaccine endorsement, the items in this section of the 
survey were specific to 11- and 12-year-old patients.
To explore the broader context of physician communication, our survey addressed two 
vaccine-related policies. First, physicians indicated whether their clinics or practices have a 
policy to dismiss families who refuse vaccines for their children. If yes, a follow-up item 
assessed whether the policy applies to refusal of each of the adolescent vaccines. Second, 
physicians indicated the extent to which having school entry requirements for Tdap, but not 
HPV vaccine, makes some parents think HPV vaccine is less important. For this item, a 
five-point response scale ranged from “strongly disagree” to “strongly agree.”
Gilkey et al. Page 3













On sample characteristics, our survey assessed physicians’ sex, medical specialty, and years 
of experience in practice. Physicians indicated the number of adolescent patients, ages 11 
through 17, they see in a typical week, as well as the percentage of adolescent vaccine doses 
they deliver through the Vaccines for Children (VFC) program. VFC is a federally-funded 
program that provides free vaccines for vulnerable populations, including uninsured and 
Medicaid-eligible youth.16 Physicians indicated their clinic or practice type (private versus 
other), size in terms of total number of physicians, and geographic location by state. We 
categorized locations into national regions using U.S. Census classifications.17
To assess and improve the clarity of survey items, we conducted cognitive testing with nine 
physicians. The survey company subsequently pilot tested the survey with 60 additional 
physicians to ensure proper functioning. The survey instrument is available at www.unc.edu/
~ntbrewer/hpv.htm.
Statistical analysis
To compare physicians’ responses about HPV vaccine to their responses about Tdap and 
meningococcal vaccines, we used McNemar’s tests for dichotomous variables and paired t-
tests for continuous variables. In exploratory analyses, we repeated these tests for key 
variables after stratifying by physician specialty. Statistical tests were two-tailed with a 




Respondents were pediatricians (53%) and family physicians (47%) (Table 1). About two-
thirds (68%) were male. Over half (55%) had 20 or more years of experience, and most 
(85%) were in private practice. The sample included physicians working in 48 of 50 U.S. 
states, and each geographic region was well represented.
HPV vaccine perceptions and communication practices
Physicians’ perceptions of adolescent vaccine endorsement varied by vaccine type and by 
whether they were rating themselves or parents (Figure 1). In terms of their own 
communication, about three-quarters of physicians (73%) reported highly endorsing HPV 
vaccine when recommending it for patients, ages 11–12. By comparison, more physicians 
highly endorsed Tdap (95%) and meningococcal (87%) vaccines (both p<0.001). Just 13% 
of physicians indicated that parents highly endorse HPV vaccine for their 11- and 12-year-
old children. Physicians more often perceived parents as highly endorsing Tdap (74%) and 
meningococcal (62%) vaccines (both p<0.001). For each of the three vaccines, physicians 
more often rated their own endorsement highly than parents’ (all p<0.001).
About two-thirds of physicians (64%) reported that, for patients ages 11–12, they usually 
discuss adolescent vaccines in a particular order. Of those 494 physicians with a preferred 
order, 361 physicians (73%) discussed Tdap first, and 347 (70%) discussed HPV vaccine 
last (Figure 2). On average, physicians estimated that talking about HPV vaccine for 11- and 
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12-year-old patients usually takes 3.7 minutes (standard error [SE]=0.12), which was longer 
than their estimates for Tdap (mean=1.9 minutes, SE=0.09, p<0.001) and meningococcal 
(mean=2.2 minutes, SE=0.12) vaccines (both p<0.001, Figure 3).
Fewer than half of physicians (41%) reported discussing adolescent vaccines at sick visits 
for 11- and 12-year-old patients with mild complaints. Of those 322 physicians who did, 235 
physicians (73%) indicated they discuss HPV vaccine. Physicians more often discussed 
other adolescent vaccines at sick visits, with 288 (89%, p<0.001) indicating they discuss 
Tdap and 263 (82%, p<0.01) indicating meningococcal vaccine. Among 567 physicians who 
did not discuss one or more adolescent vaccines during sick visits, 418 physicians (74%) 
reported that vaccination is better suited for a well visit, 192 (34%) reported vaccination 
takes too long to discuss, and 188 (33%) reported that parents may blame the vaccine if the 
child’s illness worsens. Among less commonly endorsed reasons for not discussing 
adolescent vaccines at sick visits, 60 physicians (11%) indicated inadequate reimbursement 
and 24 (4%) indicated extra paperwork.
Vaccine-related policies
One-quarter (25%) of physicians worked in practices or clinics with a policy to dismiss 
families who refused early childhood or adolescent vaccines. Among those 193 physicians 
who did, 24 (12%) indicated the dismissal policy applied to HPV vaccine. Dismissal policies 
more often applied to other adolescent vaccines, with 88 physicians (46%) indicating that 
the policy applied to Tdap and 72 (37%) indicating meningococcal vaccine (both p<0.001). 
About three-quarters of physicians (74%) somewhat or strongly agreed that having a school 
entry requirement for Tdap, but not HPV vaccine, makes some parents think HPV vaccine is 
less important.
Differences by physician specialty
In exploratory analyses stratified by physician specialty, pediatricians generally rated their 
perceptions and communication practices related to adolescent vaccination more positively 
than family physicians did; however, both specialties consistently rated HPV vaccine more 
negatively than other adolescent vaccines. On physician endorsement, 77% of pediatricians 
and 69% of family physicians reported recommending HPV vaccine as highly important for 
patients, ages 11–12. Pediatricians and family physicians more often recommended Tdap 
(99% and 91%, respectively, both p<0.001) and meningococcal vaccines (96%, p<0.001 and 
76%, p<0.01) as highly important for this age group. On parental endorsement, 9% of 
pediatricians and 17% of family physicians believed that parents feel HPV vaccine is highly 
important for their 11- and 12-year-old children. A higher percentage of pediatricians and 
family physicians perceived parental endorsement for Tdap (83% and 63%, both p<0.001) 
and meningococcal vaccines (72% and 49%, both p<0.001). Pediatricians and family 
physicians estimated that talking about HPV vaccine for 11- and 12-year-old patients 
usually took 3.4 minutes and 3.9 minutes, respectively, which was longer than their 
estimates for Tdap (1.6 and 2.2 minutes, both p<0.001) and meningococcal vaccines (1.9 
and 2.6 minutes, both p<0.001).
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Pediatricians and family physicians in our national study reported communicating about 
HPV vaccine differently from other adolescent vaccines. For 11- and 12-year-old patients, 
physicians indicated that they endorsed HPV vaccine less strongly than Tdap or 
meningococcal vaccines and often discussed it last. These findings add to a growing 
literature which suggests that, although physicians generally support HPV 
vaccination,11,18,19 they discuss it in ways that likely discount its value.11–14 To the extent 
that physicians’ strong endorsements of Tdap or meningococcal vaccines serve as a 
reference point for decision making,20,21 parents may perceive more moderate endorsement 
of HPV vaccine as indicative of physicians’ ambivalence or even concern. Similarly, 
discussing HPV vaccine last may signal to parents that it is less important than other 
vaccines. Given that these communication practices are modifiable, future studies should 
investigate the extent to which relative vaccine endorsement and discussion order influence 
parents’ willingness to vaccinate.
Physicians in our study perceived little support for HPV vaccination among parents of 11- 
and 12-year-old children. Although a majority of physicians reported that parents felt that 
Tdap and meningococcal vaccines were “very” or “extremely” important, only 13% said the 
same for HPV vaccine. Prior studies have also shown, albeit less dramatically, that providers 
view parents as a key barrier to HPV vaccination.11–13,22 For example, in a statewide 
sample of Minnesotan vaccine providers, we found that half of respondents reported that 
parents request to delay HPV vaccination for younger adolescents “often” or “most of the 
time.”13 Interestingly, these perceptions of strong parental hesitancy are generally at odds 
with research among parents themselves, which finds that a majority value HPV vaccine, are 
willing to vaccinate, and would prefer to receive strong recommendations from their 
children’s providers.4,11,14,23–24 Most of the physicians in our study reported that not having 
school entry requirements for HPV vaccine contributed to parental hesitancy, and this 
finding may offer one clue as to why physicians perceive communication about HPV 
vaccine to be burdensome. Without the supportive policy environments which surround 
Tdap and, to a lesser extent, meningococcal vaccination,25 physicians are left to make a case 
for HPV vaccination without recourse to the law.
One of our study’s most notable findings is that physicians estimated the average length of 
discussions for HPV vaccination to be well over three minutes, or almost twice as long as 
for Tdap. The additional time required to discuss HPV vaccination likely reflects the need to 
address parental hesitancy, which, as previously noted, physicians perceived as being 
widespread. Ironically, physicians’ own hesitancy may also play a role. Research suggests 
that more circumspect or open-ended communication styles prompt questions and concerns 
among parents when compared to directive approaches that “expect a yes.”11,26 To the 
extent that physicians use open-ended communication styles to recommend HPV 
vaccination, they may be inadvertently contributing to parental hesitancy and, in turn, 
discussion length. Whatever its cause, a discussion length of over three minutes constitutes a 
substantial time commitment in the context of a standard 15- to 20-minute well-child visit 
and likely poses a considerable barrier to HPV vaccination.27 Our findings suggest that 
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strategies are urgently needed for helping physicians communicate about HPV vaccination 
more efficiently.
Fewer than half of the physicians in our study usually discussed adolescent vaccination at 
sick visits for 11- and 12-year-old patients with mild complaints, and only about one-third 
usually discussed HPV vaccination specifically. When prompted to give a reason for not 
broaching adolescent vaccination at sick visits, physicians most often reported believing that 
vaccination is better suited to well-child visits. This view is at odds with practice guidelines 
which state that mild illnesses, such as upper respiratory tract infections with or without 
fever, do not constitute grounds for delaying vaccination.28 Our findings suggest that 
immunization quality improvement programs that encourage physicians and other vaccine 
providers to “use every opportunity” to deliver HPV vaccine will likely encounter 
resistance.29 Additional education on contraindications and precautions for HPV vaccine 
administration may be needed to overcome physicians’ preference for delaying adolescent 
vaccination until well-child visits.
In terms of differences by physician specialty, both pediatricians and family physicians 
viewed HPV vaccine more negatively than other adolescent vaccines. Both groups reported 
that they recommended HPV vaccine less strongly than Tdap or meningococcal vaccines, 
perceived less parental support for it, and took longer to discuss it. At the same time, except 
in the case of parental endorsement for HPV vaccination, family physicians reported more 
negative perceptions than pediatricians across the adolescent platform, and sometimes 
dramatically so. For example, although almost all pediatricians reported recommending 
meningococcal vaccine strongly for 11- and 12-year-old patients, only about three-quarters 
of family physicians did so. Family physicians also reported perceiving far less parental 
support for Tdap and meningococcal vaccines than pediatricians did. These findings are 
consistent with prior studies which have shown that pediatricians are generally more 
supportive of vaccination, including adolescent vaccination, than other physicians.30,31 In 
terms of communication interventions, our findings suggest that family physicians may 
benefit from programs with a focus on adolescent vaccination more broadly, rather than on 
HPV vaccination alone. Future research is needed to explore other potential sources of 
subgroup variation in physician communication about adolescent vaccination such as 
practice setting, patient mix, or perceptions of vaccine cost.
Strengths of this cross-sectional study include data from a large, national sample of 
pediatricians and family physicians. Physicians practicing in these specialties are 
particularly important to immunization quality improvement because they deliver the 
majority of HPV vaccine doses in the U.S. Limitations to this study include a modest 
response rate, which is a common challenge for physician surveys.32 The self-reported 
nature of physician communication variables, such as strength of vaccine endorsement, is 
also a limitation because social desirability may have prompted physicians to overestimate 
their support for vaccines. Nevertheless, by collecting data on all three adolescent vaccines, 
we were able to describe relative differences, thereby contextualizing communication about 
HPV vaccination and somewhat offsetting the limitations of individual measures. Future 
research can extend the present study by exploring differences in physician communication 
about adolescent vaccination from other perspectives, including those of adolescent patients 
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and their parents. Finally, this study is limited to communication about vaccines in the 
adolescent platform. Physician communication about early childhood vaccination likely 
differs from our findings in important ways and may hold additional insights into strategies 
that physicians can use for partnering with parents to increase vaccination coverage.
Conclusions
Parents do not make decisions about HPV vaccination in a vacuum, but rather consider HPV 
vaccine alongside other vaccines and health services as they negotiate medical encounters 
with their children’s healthcare providers. The findings of this study suggest that the 
messages parents receive about HPV vaccine, relative to other adolescent vaccines, are not 
encouraging. Pediatricians and family physicians in our national sample reported that they 
endorse HPV vaccine less strongly than Tdap or meningococcal vaccines, often discuss it 
last, and rarely recommend it for patients with mild illnesses. These suboptimal 
communication practices likely discourage parents from vaccinating their children and may 
also contribute to the extended discussion length and profound parental hesitancy that 
physicians in this study reported with regard to HPV vaccination. Our findings suggest that, 
in the absence of supportive policies, better communication strategies are needed to help 
physicians recommend HPV vaccine with greater confidence and efficiency. By modifying 
factors such as relative vaccine endorsement and discussion order, physicians may be able to 
better communicate that HPV vaccination is not an exception to adolescents’ routine 
immunization schedule, but rather an effective and safe health service that is critical to the 
prevention of genital warts and HPV-attributable cancers.
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• Physician communication about adolescent vaccination varied by vaccine type.
• Physicians endorsed HPV vaccine less strongly than Tdap or meningococcal 
vaccines.
• They perceived HPV vaccine discussions as taking longer and garnering less 
support.
• They often discussed HPV vaccine last.
• These suboptimal communication practices likely discourage timely HPV 
vaccination.
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Physicians’ perceptions of adolescent vaccine endorsement for patients, ages 11 and 12, 
2014, USA (n=776). Standard error for each proportion was less than 0.02.
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Vaccines physicians discuss first and last, among those with a preferred order, for patients, 
ages 11 and 12, 2014, USA (n=494).
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Time physicians usually take to discuss adolescent vaccines for patients, ages 11 and 12 
(n=776), 2014, USA. Bars show standard error.
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Table 1
Sample characteristics, 2014, USA (n=776).
n (%)
Physician characteristics
  Medical specialty
    Pediatrics 410 (53)
    Family practice 366 (47)
  Sex
    Male 526 (68)
    Female 250 (32)
  Years in practice
    ≤19 352 (45)
    ≥20 424 (55)
  Adolescent patients seen in typical week
    ≤9 129 (17)
    10–24 351 (45)
    ≥25 296 (38)
  Vaccine doses through VFC
    ≤9% 290 (37)
    10%–49% 274 (35)
    ≥50% 152 (20)
    Not sure 60 (8)
Clinic or practice characteristics
  Type
    Private practice (solo, group, HMO) 660 (85)
    Othera 116 (15)
  Total physicians
    1–4 398 (51)
    5–9 217 (28)
    ≥10 161 (21)
  Region
    Northeast 184 (24)
    Midwest 165 (21)
    South 275 (35)
    West 152 (20)
Note. HMO: health maintenance organization. HPV: human papillomavirus. VFC: Vaccines for Children.
a
Includes hospital- and university-based clinics, Federally Qualified Health Centers, and community, rural, migrant, Indian, military, public health, 
and school health clinics.
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